Core Insights - The study indicates that SUBLOCADE, an extended-release buprenorphine injection, may significantly reduce staff time and associated costs in jails and prisons compared to other medications for opioid use disorder (MOUD) [1][2][3] Group 1: Cost Impact Model Findings - The model estimates that using monthly injectable buprenorphine requires fewer staff hours than other MOUD treatments, with reductions of 318 hours compared to methadone, 747 hours compared to oral buprenorphine, 192 hours compared to weekly extended-release buprenorphine, and 6 hours compared to extended-release naltrexone [7] - The estimated monthly cost savings from reduced staff time range from $23 to $22,148, with the largest savings resulting from the elimination of daily observed dosing and patient escorts [7] Group 2: Staffing Challenges in Correctional Facilities - Correctional facilities are facing ongoing staffing constraints as the demand for MOUD continues to grow, with nearly half of U.S. jails and prisons citing staffing as a primary barrier to providing MOUD [2][3] - The findings suggest that monthly injectable buprenorphine can alleviate the dosing burden and staff involvement, allowing facilities to operate more efficiently while expanding access to evidence-based care [2][3] Group 3: Study Background and Limitations - The study was funded by Indivior and conducted in collaboration with Veradigm and researchers from the University of Kentucky College of Medicine [4] - Limitations of the study include the exclusion of medication acquisition costs and some administration times based on assumptions due to a lack of available data [3]

Core Insights - Indivior Pharmaceuticals is a key player in long-acting injectable treatments for opioid use disorder (OUD), focusing on evidence-based solutions like SUBLOCADE, which is a monthly injectable form of buprenorphine aimed at improving patient outcomes and reducing healthcare costs [1] - A recent study indicates that patients adhering to SUBLOCADE for 12 months experienced a 42% reduction in non-MOUD medical costs, supporting the company's strategy to evaluate OUD treatment based on total healthcare costs [1] Financial Performance - Indivior's stock (INDV) has a price-to-earnings (P/E) ratio of 18, reflecting investor confidence in its earnings potential [2] - The company faces financial challenges, indicated by a negative enterprise value to operating cash flow ratio of -207.20 and a debt-to-equity ratio of -3.58, suggesting potential difficulties in cash flow generation and financial structuring [2] - The current ratio of 0.71 indicates that Indivior may struggle to cover short-term liabilities with its short-term assets [3] Industry Position - Despite financial challenges, Indivior's focus on long-acting injectable treatments and evidence-based care positions it as a leader in addressing OUD, which is recognized as a chronic but treatable brain disease [3]

Core Insights - Indivior Pharmaceuticals announced findings from a study indicating that adherence to SUBLOCADE is linked to significantly lower healthcare utilization and costs for patients with opioid use disorder (OUD) compared to other medications and nonadherent patients [1][5][8] Group 1: Study Findings - The study published in Frontiers in Public Health shows that patients adhering to SUBLOCADE had 42% lower adjusted non-MOUD medical costs, amounting to $15,017 less annually per patient compared to those adhering to other forms of MOUD [8][9] - Patients on SUBLOCADE experienced the lowest rates of inpatient admissions, emergency department visits, and detoxification services, highlighting the treatment's effectiveness in reducing acute healthcare needs [4][8] - The study reinforces the importance of evaluating OUD treatment based on total healthcare costs, suggesting that long-acting therapies like SUBLOCADE can lead to system-wide savings while improving patient care continuity [6][9] Group 2: Treatment Context - SUBLOCADE is indicated for the treatment of moderate to severe OUD and should be part of a comprehensive treatment plan that includes counseling and psychosocial support [10] - The study's findings contribute to the growing evidence that long-acting injectable buprenorphine treatments support sustained engagement in care and reduce costly acute healthcare use [2][5] - Indivior is positioned as a leader in long-acting injectable treatments for OUD, focusing on evidence-based treatment and advancing the understanding of OUD as a chronic but treatable condition [22]

Core Insights - Indivior PLC completed the 'Generate Momentum' phase in 2025 and is transitioning to the 'Accelerate' phase in 2026 to enhance SUBLOCADE dispense unit growth and margin expansion [6] - The company reported record SUBLOCADE net revenue of $856 million in 2025, reflecting a 13% year-over-year increase attributed to improved commercial execution [6] - Indivior aims to cap 2026 operating expenses at $450 million by simplifying its organizational structure [6] Financial Performance - The balance sheet was strengthened by settling a $295 million legacy DOJ obligation, removing a significant long-term liability [6] - The guidance for 2026 anticipates an acceleration of SUBLOCADE dispense unit growth to the mid-teens, up from 7% in 2025 [6] - Projected total net revenue for 2026 is estimated between $1.125 billion and $1.195 billion, driven by SUBLOCADE growth but offset by SUBOXONE Film erosion and lower net revenue from optimization efforts [6] Strategic Initiatives - Launched the 'Move Forward in Recovery' DTC campaign to address the underutilization of long-acting injectables (LAIs), which currently have only 9% market penetration [6] - The strategic roadmap includes 'Phase 3: Breakout,' focusing on acquiring commercial-stage assets in new therapeutic areas to diversify the portfolio [6] - A new $400 million share repurchase program has been authorized to be utilized opportunistically based on valuation gaps [6] Operational Adjustments - Recorded $120 million in restructuring charges for 2025 related to headcount reductions, footprint consolidation, and R&D reprioritization [6] - Identified gross-to-net (GTN) dynamics as a $49 million tailwind in 2025, expected to become a headwind in 2026 [6] - The 2026 R&D budget accounts for potential Phase III advancements for pipeline assets INDV-2000 and INDV-6001 pending Q2 data readouts [6]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenue of $856 million for SUBLOCADE, a 13% increase compared to 2024, and total net revenue of $1.24 billion, representing a 4% increase year-over-year [5][19] - Adjusted EBITDA grew 20% year-over-year to $428 million in 2025, with notable margin improvement [5][24] - Operating expenses are projected to not exceed $450 million in 2026 [5] Business Line Data and Key Metrics Changes - SUBLOCADE dispense volume grew 12% year-over-year in Q4 and 6% compared to Q3, with new patient starts up 25% year-over-year [12][20] - Total SUBLOCADE net revenue for Q4 was $252 million, a 30% increase year-over-year [20] - SUBOXONE Film net revenue benefited from continued generic price stability, with Q4 net revenue including a gross benefit of $23 million [21] Market Data and Key Metrics Changes - The long-acting injectables (LAIs) category saw growth approaching 18% in Q4 2025 [40][44] - The company reported stabilization of SUBLOCADE's market share in the mid-70s [13][34] Company Strategy and Development Direction - The company is executing phase II of the Indivior Action Agenda, focusing on accelerating SUBLOCADE dispense unit growth and net revenue throughout 2026 [8][28] - A new $400 million share repurchase program has been authorized to return value to shareholders [7][27] - The company aims to strategically deploy capital to create long-term value, focusing on managing debt and evaluating business development opportunities [10][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum and the potential for SUBLOCADE, emphasizing that long-acting injectables remain underutilized [9][34] - The company expects to deliver SUBLOCADE dispense unit growth in the mid-teens in 2026, an acceleration from the 7% growth achieved in 2025 [9][25] - Management is optimistic about the engagement from the direct-to-consumer campaign launched in October 2025, which has shown early indicators of success [16][17] Other Important Information - The company eliminated a significant future liability by paying the outstanding $295 million obligation related to a legacy DOJ matter [6][26] - The company ended 2025 with gross cash and investments of $222 million, with net leverage below one time [26] Q&A Session Summary Question: Thoughts on LAI buprenorphine modalities penetration and market share - Management believes there is significant opportunity for LAI penetration, currently at 9%, with potential growth to 20%-30% based on market research [33][34] Question: Guidance assumptions for LAI market growth and share in 2026 - Management expects mid-teen SUBLOCADE growth and continued stabilization of market share [41][42] Question: Medicaid funding landscape impact on SUBLOCADE - Management is optimistic about Medicaid support and believes there is substantial growth opportunity for SUBLOCADE regardless of Medicaid funding fluctuations [51][52] Question: Shape of SG&A in 2026 and DTC spending - Management indicated that DTC spending is a priority and will be maintained for a multi-year period to drive long-acting injectable penetration [51] Question: Contribution from the criminal justice system to SUBLOCADE guidance - Management sees the criminal justice segment as a strong opportunity for growth, contributing to the overall guidance for mid-teens growth [67] Question: Expectations for SUBLOCADE ex U.S. revenues - Management anticipates relatively flat year-over-year revenues for SUBLOCADE outside the U.S., with growth in some regions offset by declines in others [71]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenue of $1.24 billion, a 4% increase compared to the previous year, with SUBLOCADE net revenue reaching $856 million, reflecting a 13% increase year-over-year [5][19] - Adjusted EBITDA grew by 20% year-over-year to $428 million, with a margin improvement of 500 basis points [5][24] - Operating expenses are projected to not exceed $450 million in 2026, indicating a focus on cost management [5][10] Business Line Data and Key Metrics Changes - SUBLOCADE dispense volume grew by 12% year-over-year in Q4 and 7% for the full year, indicating strong demand for the product [12][20] - The company launched a direct-to-consumer campaign, "Move Forward in Recovery," which has shown early signs of success, including a 60% increase in branded online search volume [16][17] Market Data and Key Metrics Changes - The long-acting injectables (LAIs) market is experiencing growth, with the company reporting a category growth of approximately 18% in Q4 2025 [40][44] - The company maintains a market share in the mid-70s for SUBLOCADE, with new patient starts achieving all-time highs [13][34] Company Strategy and Development Direction - The company is executing phase two of the Indivior Action Agenda, focusing on accelerating SUBLOCADE growth and enhancing adjusted EBITDA and cash flow [8][28] - The capital deployment strategy includes managing debt, a $400 million share repurchase program, and evaluating business development opportunities for growth drivers [10][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's ability to accelerate growth in 2026, with expectations of mid-teens dispense unit growth for SUBLOCADE [9][41] - The company believes long-acting injectables remain underutilized, presenting significant growth opportunities [9][33] Other Important Information - The company eliminated a significant future liability by paying a $295 million obligation related to a legacy DOJ matter [6][7] - The company ended 2025 with gross cash and investments of $222 million, positioning itself well for future investments [26] Q&A Session Summary Question: Thoughts on LAI penetration and market share - Management believes there is significant opportunity for LAI penetration to grow from the current 9%, with potential analogs suggesting a range of 20%-30% [33][34] Question: Guidance assumptions for LAI market growth in 2026 - The guidance assumes mid-teen SUBLOCADE growth, with continued stabilization of market share [41][42] Question: Medicaid funding landscape impact on SUBLOCADE - Management is optimistic about Medicaid support for opioid use disorder treatments and believes growth opportunities exist regardless of funding fluctuations [51][52] Question: Shape of SG&A in 2026 and DTC spending - Management indicated that DTC spending is a priority, with a commitment to over-invest in patient education and engagement [51][53] Question: Contribution from the criminal justice system to SUBLOCADE guidance - The criminal justice segment is viewed as a strong opportunity for growth, contributing to the overall LAI category expansion [67]

Core Insights - Indivior Pharmaceuticals reported strong financial results for Q4 and full year 2025, with a focus on accelerating growth in 2026 through its Indivior Action Agenda [2][4][5] Financial Performance - Total SUBLOCADE net revenue reached $856 million for FY 2025, a 13% increase year-over-year, with Q4 2025 net revenue at $252 million, up 30% year-over-year [4][5][10] - GAAP net income for FY 2025 was $210 million, compared to $7 million in FY 2024, while non-GAAP net income was $320 million, up from $240 million [10][45] - Adjusted EBITDA for FY 2025 was $428 million, representing a 20% increase from FY 2024 [10][48] Business Strategy - The company has entered Phase II of the Indivior Action Agenda, focusing on accelerating SUBLOCADE growth and improving cash flow [2][4] - A new $400 million share repurchase program has been authorized to enhance shareholder value [4][5] Operational Highlights - U.S. SUBLOCADE net revenue increased by 13% to $794 million for FY 2025, driven by a 7% growth in dispense unit volume [5][31] - A nationwide direct-to-consumer campaign was launched to raise awareness of SUBLOCADE and long-acting injectables for opioid use disorder [5][12] Future Guidance - For FY 2026, the company expects total net revenue between $1,125 million and $1,195 million, with SUBLOCADE net revenue projected between $905 million and $945 million [6][7] - Operating expenses are expected to be managed within $430 million to $450 million, with adjusted EBITDA anticipated between $535 million and $575 million [6][7]

Core Viewpoint - Indivior PLC has announced its full-year 2026 financial guidance, indicating a strong growth trajectory for its SUBLOCADE product and overall financial performance [2][4]. Financial Guidance - Total net revenue is expected to be in the range of $1,125 million to $1,195 million [4][8]. - Total SUBLOCADE net revenue is projected to be between $905 million and $945 million [4][8]. - Non-GAAP operating expenses are anticipated to be in the range of $430 million to $450 million [4][8]. - Adjusted EBITDA is expected to be between $535 million and $575 million [4][8]. Business Strategy and Highlights - 2025 was identified as a transition year, with the completion of Phase I of the Indivior Action Agenda, focusing on generating momentum through revenue growth and organizational simplification [2][9]. - The company has entered Phase II of the Indivior Action Agenda, which aims to accelerate SUBLOCADE dispense unit growth and net revenue throughout 2026 [2][9]. - Indivior gained inclusion in the S&P SmallCap 600 index effective December 22, 2025 [9]. - The company received shareholder approval to change its domicile from the U.K. to the U.S., with the new U.S. parent company expected to be established by January 26, 2026 [9]. - Indivior has resolved a legacy U.S. Department of Justice matter by paying a total of $295 million [9]. Growth Projections - The company expects SUBLOCADE net revenue growth of 11% at the midpoint of its guidance range [2]. - Adjusted EBITDA is projected to grow by 35%, with an adjusted EBITDA margin increase of 14 percentage points [2].

Company Overview - Indivior PLC is a specialty pharmaceutical company focused on treating opioid use disorder and related behavioral health conditions, utilizing a diverse portfolio of proprietary therapies and innovative pipeline assets [1] - The company primarily generates revenue through the sale of branded pharmaceutical products, particularly long-acting injectable therapies and sublingual formulations targeting opioid use disorder [2] Financial Performance - In the third quarter, Indivior reported $314 million in revenue, with SUBLOCADE sales increasing by 15% year over year to $219 million, contributing to a 14% rise in adjusted EBITDA to $120 million [5] - Management has raised the full-year 2025 revenue guidance to between $1.18 billion and $1.22 billion, with adjusted EBITDA projected to reach up to $420 million, alongside a plan for at least $150 million in annual operating expense savings starting next year [5] Stock Performance - As of the latest report, Indivior shares were priced at $36.21, reflecting a significant increase of 194% over the past year, outperforming the S&P 500, which rose about 15% during the same period [3] Investor Activity - Stonepine Capital Management sold 250,000 shares of Indivior during the third quarter, resulting in a decrease in the fund's position value by approximately $2.75 million, leaving them with 100,000 shares valued at $2.41 million at quarter-end [4] - The sale appears to be a strategic decision rather than a lack of confidence, as Indivior still represents a meaningful exposure in Stonepine's portfolio relative to other biotech names [6]

Group 1 - Indivior PLC has been added to the S&P SmallCap 600 index, effective December 22, 2025, marking a significant milestone for the company [1][2] - The inclusion in the S&P SmallCap 600 aligns Indivior's capital markets presence with its enhanced U.S. business profile, as stated by the CEO Joe Ciaffoni [2] - The S&P SmallCap 600 index consists of 600 U.S. companies with market capitalizations between $1.2 billion and $8.0 billion, designed to track liquid and financially viable companies [2] Group 2 - Indivior Pharmaceuticals focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [3] - The company is committed to expanding its portfolio of OUD treatments and has a pipeline of product candidates to enhance its offerings in this category [3]